共 50 条
Curative gene therapies for rare diseases
被引:16
|作者:
Maldonado, Rocio
[1
]
Jalil, Sami
[1
]
Wartiovaara, Kirmo
[1
,2
]
机构:
[1] Univ Helsinki, Stem Cells & Metab Res Program, Helsinki, Finland
[2] Helsinki Univ Hosp, Clin Genet, Helsinki, Finland
基金:
芬兰科学院;
关键词:
CRISPR-Cas9;
Gene therapy;
Genetic engineering;
FETAL-HEMOGLOBIN;
VISUAL RECOVERY;
LYMPHOCYTES;
CELLS;
TRIAL;
REPLACEMENT;
DEFICIENCY;
MECHANISMS;
DELIVERY;
D O I:
10.1007/s12687-020-00480-6
中图分类号:
Q3 [遗传学];
学科分类号:
071007 ;
090102 ;
摘要:
Diseases caused by alterations in the DNA can be overcome by providing the cells or tissues with a functional copy of the mutated gene. The most common form of gene therapy implies adding an extra genetic unit into the cell. However, new genome engineering techniques also allow the modification or correction of the existing allele, providing new possibilities, especially for dominant diseases. Gene therapies have been tested for 30 years in thousands of clinical trials, but presently, we have only three authorised gene therapy products for the treatment of inherited diseases in European Union. Here, we describe the gene therapy alternatives already on the market in the European Union and expand the scope to some clinical trials. Additionally, we discuss the ethical and regulatory issues raised by the development of these new kinds of therapies.
引用
收藏
页码:267 / 276
页数:10
相关论文